15522676233
15522676233
新聞資訊
更新時間：2021-09-30
點擊次數(shù)：1093
Synthose公司位于加拿大多倫多，由 Eva Goss 博士于 2006 年創(chuàng)立。團隊由多名碳水化合物專家組成，創(chuàng)新的工藝開發(fā)以及超過1000種的碳水化合物和糖綴合物，在提供資源問題解決方案迅速獲得認可。公司專門為化學(xué)，生物化學(xué)，生物能源和治療研究領(lǐng)域提供合成化合物，產(chǎn)品覆蓋化學(xué)、生物學(xué)、藥物開發(fā)和生物燃料領(lǐng)域。
Synthose Inc. is a group of carbohydrate synthesis specialists with an R&D and manufacturing laboratory just north of Toronto in Canada.
Established in 2006 as LC Scientific Inc. by Dr. Eva Goss, in 2016 we moved to a larger facility and changed our name to Synthose to better reflect our focus on the synthesis of carbohydrates and glycoconjugates.
Synthose部分產(chǎn)品列表：
貨號 | 產(chǎn)品 | 規(guī)格 |
AA700L | D-Allose-1,2,3,4,5,6-13C6 | 100mg |
BA406 | 3-O-Benzyl-1,2:5,6-di-O-isopropylidene-α-D-allofuranose | 10g |
DA945 | 3-Deoxy-3-fluoro-D-allose | 10mg |
TA358 | 1,2,4,6-Tetra-O-acetyl-3-deoxy-3-fluoro-β-D-allopyranoside | 25mg |
AG546 | Allyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside | 10g |
CG449 | 4-Cyclohexylbutyl β-D-glucopyranoside | 500mg |
DX114 | 2-Decyltetradecyl D-xylopyranoside | 100mg |
DX216 | 2-Dodecylhexadecyl D-xylopyranoside | 100mg |
DX812 | 2-Octyldodecyl D-xylopyranoside | 100mg |
EX226 | 2-Ethylhexyl D-xylopyranoside | 100mg |
HX610 | Hexadecyl β-D-xylopyranoside | 100mg |
AD332 | 6"-O-Acetyldaidzin | 1mg |
AD345 | 6"-O-Acetylgenistin | 1mg |
CG872 | Caffeic acid 3-O-β-D-glucopyranoside | 2mg |
DG214 | 3,4-Dideoxyglucosone-3-ene | 1mg |
DG216 | 3-Deoxy-D-glucosone | 10mg |
AG823 | 3-Acetylumbelliferyl β-D-glucopyranoside | 10mg |
AL854 | 5-Acetamidofluorescein di-(β-D-galactopyranoside) | 10mg |
BG855 | 5-Bromo-4-chloro-3-indolyl β-D-cellotetraoside | 1mg |
DD832 | 6,8-Difluoro-4-methylumbelliferyl O-β-D-glucuronide | 25mg |
DG834 | 6,8-Difluoro-4-methylumbelliferyl β-D-glucopyranoside | 10mg |
IG850 | 3-Indolyl β-D-cellotrioside | 1mg |
了解更多詳情，
請掃描下方二維碼，
關(guān)注百奧創(chuàng)新公眾號！
關(guān)注我們
Copyright © 2025北京百奧創(chuàng)新科技有限公司 All Rights Reserved 工信部備案號：京ICP備17019404號-2
技術(shù)支持：化工儀器網(wǎng) 管理登錄 sitemap.xml
當前位置：
上一個：
返回列表